Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Katrina Mayol"'
Autor:
Seng Lor Saelee, Alexander F. Lovejoy, Bernd Hinzmann, Katrina Mayol, Samantha Huynh, Amy Harrell, Josh Lefkowitz, Niharika Deodhar, Gladys Garcia-Montoya, Stephanie J. Yaung, Daniel M. Klass
Publikováno v:
The Journal of Molecular Diagnostics. 24:566-575
Cell-free (cf)DNA-based testing has undergone increasingly wide adoption, including assays for the detection of circulating tumor DNA. Due to nucleosome protection, cfDNA has a distinctive fragment size of 160 to 180 bp. However, cfDNA can be contami
Autor:
Seng Lor Saelee, Katrina Mayol, Abraham Munoz, Paul W. Shi, Alex Lovejoy, Amrita Pati, Vera Rapoport, Janet Jin, Dan Klass
Publikováno v:
Cancer Research. 78:4574-4574
A key technical challenge in oncology is the detection of minimal residual disease (MRD, the presence of residual tumor in a subject post-treatment). Recent studies have shown poor prognostic outcomes for research subjects with ultra-low residual tum
Autor:
John F. Palma, Christoph Mancao, Alan Nicholas, Carolyn Williams, May Yau, Nasiema Wingate-Pearse, Lijing Yao, Nicolas Sommer, Monica Pimentel, David Zhang, Johanna C. Bendell, John Lee, Abraham Munoz, Stephanie J. Yaung, Katrina Mayol, Herbert Hurwitz, Alexander F. Lovejoy, Ulrich Peter Rohr
Publikováno v:
Journal of Clinical Oncology. 35:e15118-e15118
e15118 Background: STEAM (NCT01765582) evaluated the efficacy and safety of concurrent (c) and sequential (s) FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for first-line treatment of mCRC. Methods: The AVENIO ctDNA Expanded Kit (Research Use Only) w
Autor:
Ulrich Peter Rohr, May Yau, Nasiema Wingate-Pearse, Johanna C. Bendell, Lijing Yao, David Zhang, Nicolas Sommer, Alexander F. Lovejoy, Monica Pimentel, Abraham Munoz, Alan Nicholas, John F. Palma, John Lee, Carolyn Williams, Stephanie J. Yaung, Katrina Mayol, Herbert Hurwitz, Christoph Mancao
Publikováno v:
Journal of Clinical Oncology. 35:11510-11510
11510 Background: STEAM (NCT01765582) assessed the efficacy and safety of concurrent (c) and sequential (s) FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for first-line treatment of mCRC. Methods: The AVENIO ctDNA Expanded Kit (Research Use Only) was use